Apogee Therapeutics, Inc. Common Stock
APGE
$133.82
+0.13%
Apogee Therapeutics is a clinical-stage biotechnology company focused on developing optimized biologics for inflammatory and immunology (I&I) indications, including atopic dermatitis, asthma, and COPD. As a pre-revenue biotech with a pipeline targeting well-validated mechanisms, it distinguishes itself through antibody engineering aimed at improved efficacy and dosing convenience. The stock is currently at the center of a transformative narrative following AbbVie's $10.9 billion acquisition announcement in June 2026, which has driven a massive price surge and shifted investor focus to the deal's strategic rationale and long-term accretion potential.…
APGE
Apogee Therapeutics, Inc. Common Stock
$133.82
Related headlines
Investment Opinion: Should I buy APGE Today?
Rating: Buy. The acquisition by AbbVie at a substantial premium provides a clear and near-certain upside, making APGE a compelling buy for investors seeking a low-risk arbitrage opportunity until the deal closes. The consensus analyst rating is Buy with an average target price implying upside to the acquisition value of ~$133.87.
Supporting Evidence: The acquisition price of $10.9 billion implies a per-share value of approximately $133.87, representing a 138% premium to the pre-announcement price. The stock currently trades at $133.65, offering a 0.2% upside to the acquisition price, but with low risk given the deal's strategic fit. The company has zero debt and a current ratio of 26.6, ensuring financial stability. The unanimous analyst Buy ratings and the stock's strong momentum (246.5% 1-year return) further support the thesis.
Risks & Conditions: The primary risk is deal failure, which could cause the stock to drop to the pre-announcement level of ~$90 or lower. This Buy rating would change to Hold if regulatory hurdles emerge, or to Sell if the deal is officially terminated. The stock is fairly valued relative to the acquisition price but overvalued on a standalone basis given the negative earnings and P/B premium. Investors should monitor the deal's progress closely.
Sign up to view all
APGE 12-Month Price Forecast
The AI assessment is bullish with high confidence, driven by the transformative AbbVie acquisition that de-risks the investment and provides a clear path to value realization. The stock's proximity to the acquisition price and strong technical momentum support a positive outlook. Key factors include the 138% premium, zero debt, and unanimous analyst support. The primary risk is deal failure, but the probability is low given the strategic fit. The stance would be downgraded to neutral if regulatory delays emerge, or to bearish if the deal is terminated.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Apogee Therapeutics, Inc. Common Stock's 12-month outlook, with a consensus price target around $173.97 and implied upside of +30.0% versus the current price.
Average Target
$173.97
5 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
5
covering this stock
Price Range
$107 - $174
Analyst target range
Apogee is covered by 5 analysts, with the consensus recommendation leaning bullish. All recent ratings from Mizuho, Guggenheim, Citigroup, Canaccord Genuity, and BTIG are Buy or Outperform, while RBC Capital rates it Sector Perform. The average analyst target price is not explicitly provided in the data, but based on the acquisition price of $10.9 billion and the current market cap of $4.58 billion, the implied upside is substantial. The acquisition represents a 138% premium to the pre-announcement price, and the stock has already risen significantly toward that level. The consensus is overwhelmingly positive, reflecting the de-risking nature of the acquisition.
The target range is likely narrow given the acquisition agreement, with the high target at the acquisition price (implied $133.87) and the low target possibly around the pre-announcement level ($90). The high target assumes the deal closes successfully, while the low target prices in deal failure or regulatory hurdles. The recent ratings show no downgrades; instead, analysts have maintained or reiterated Buy ratings, with BTIG reiterating Buy in March 2026. The wide spread between the current price and the acquisition price suggests high conviction in the deal's completion, but any regulatory or shareholder approval risks could cause volatility. The acquisition provides a clear valuation floor and upside, making the stock a low-risk arbitrage opportunity until closing.
Drowning in data?
Find the real signal!
Bulls vs Bears: APGE Investment Factors
Apogee Therapeutics presents a compelling bull case driven by the $10.9 billion AbbVie acquisition, which offers a clear upside to the current price and has unanimous analyst support. The company's strong balance sheet with zero debt and high liquidity further supports the positive outlook. However, bears point to the pre-revenue status with widening losses, an elevated P/B ratio relative to peers, and risks associated with the acquisition closing. The most critical tension is whether the acquisition will close successfully; if it does, the stock converges to the acquisition price, but any regulatory or shareholder hurdles could trigger a sharp decline. Currently, the bull case has stronger evidence given the acquisition's strategic rationale and the stock's proximity to the 52-week high.
Bullish
- Acquisition by AbbVie at 138% Premium: AbbVie announced a $10.9 billion acquisition of Apogee on June 22, 2026, representing a 138% premium to the pre-announcement price of ~$56. This provides a clear and substantial upside to the current price of $133.65, which is still below the implied acquisition value of ~$133.87 per share.
- Strong Momentum Near 52-Week High: The stock has surged 246.5% over the past year and is trading at 99.8% of its 52-week high of $133.87. The 1-month return of 61.6% dramatically outpaces the S&P 500's 4.1%, reflecting strong catalyst-driven momentum from the acquisition news.
- Zero Debt and High Liquidity: Apogee has a debt-to-equity ratio of 0.01 and a current ratio of 26.6, indicating a strong balance sheet with $131.5 million in cash. This financial stability reduces bankruptcy risk and supports ongoing R&D until the acquisition closes.
- Unanimous Analyst Support: All 5 analysts covering APGE rate it Buy or Outperform, with no Sell ratings. The consensus reflects confidence in the acquisition's strategic value and the company's pipeline, which targets well-validated mechanisms in immunology.
Bearish
- Pre-Revenue with Deep Losses: Apogee has zero revenue and reported a net loss of $69.4 million in Q4 2025, with losses widening from $67.2 million a year ago. The company is entirely dependent on pipeline success and the acquisition for any return.
- Elevated Valuation Without Revenue: With a P/B ratio of 5.07x versus the biotech industry average of 3.5x, the stock trades at a 45% premium. Without the acquisition, this valuation would be hard to justify given the lack of revenue and negative earnings.
- Acquisition Closing Risks: The deal requires regulatory and shareholder approvals, and any delays or failure could cause the stock to fall back to pre-announcement levels around $90, representing a 33% downside from the current price.
- High Short Interest and Low Beta: The short ratio of 9.81 days suggests significant bearish positioning, and the beta of 0.325 indicates low market correlation, meaning the stock's performance is highly dependent on company-specific events rather than market trends.
APGE Technical Analysis
Apogee is in a powerful uptrend, with the stock up 246.5% over the past year and currently trading at $133.65, representing 99.8% of its 52-week high of $133.87. This positioning near the top of the range signals strong momentum and bullish sentiment, though it also raises caution about potential overextension given the rapid recent gains. The 1-year price change of 246.5% dramatically outpaces the S&P 500's 20.6% gain, reflecting company-specific catalysts overwhelming broader market trends.
Short-term momentum is exceptionally strong, with the stock surging 61.6% in the past month and 54.9% in the past three months, far exceeding the S&P 500's 4.1% and 11.1% returns, respectively. This acceleration is directly tied to the AbbVie acquisition news on June 22, 2026, which caused a gap up from ~$90 to $132.55 in a single day. The 1-month relative strength of 57.5% versus the S&P 500 confirms the stock is being driven by idiosyncratic factors, and the divergence from the longer-term trend (which was already positive) suggests a powerful catalyst-driven breakout rather than a speculative blow-off.
Key support lies at the 52-week low of $34.34, while resistance is at the 52-week high of $133.87, which the stock is currently testing. A breakout above $133.87 would signal continued upside toward the acquisition price, while a failure could lead to a pullback toward the $90 area (pre-announcement levels). The stock's beta of 0.325 indicates it is significantly less volatile than the market, which is unusual for a biotech and may reflect the acquisition's de-risking effect; however, the recent price action shows that company-specific events can still drive substantial moves.
Beta
0.33
0.33x market volatility
Max Drawdown
-27.0%
Largest decline past year
52-Week Range
$34-$134
Price range past year
Annual Return
+250.9%
Cumulative gain past year
| Period | APGE Return | S&P 500 |
|---|---|---|
| 1m | +51.5% | +1.0% |
| 3m | +51.3% | +7.9% |
| 6m | +62.3% | +8.5% |
| 1y | +250.9% | +20.1% |
| ytd | +76.6% | +9.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
APGE Fundamental Analysis
Apogee is a pre-revenue clinical-stage biotech with zero revenue in the most recent quarter (Q4 2025) and no revenue reported in any historical period. The company has not generated any product sales, and its growth trajectory is entirely dependent on pipeline advancement and regulatory milestones. The lack of revenue means traditional growth metrics are not applicable; instead, the investment case hinges on the success of its clinical programs and the recent acquisition by AbbVie, which provides a clear exit value.
The company is deeply unprofitable, reporting a net loss of $69.4 million in Q4 2025, with losses widening from $67.2 million in Q4 2024. Gross margin is zero as there are no product revenues, and operating expenses are dominated by R&D ($58.4 million in Q4 2025) and SG&A ($20.1 million). The net loss per share was -$1.03 in Q4 2025, compared to -$1.22 in the year-ago quarter, showing a slight improvement in loss per share due to a higher share count. However, the company remains far from profitability, and the trajectory suggests continued cash burn until the acquisition closes.
Apogee has a strong balance sheet with zero debt (debt-to-equity of 0.01) and $131.5 million in cash as of Q4 2025, though this is down from $142.1 million at the end of Q3 2025. Free cash flow was negative $62.8 million in Q4 2025, and the TTM free cash flow is -$232.6 million, indicating significant cash burn. The current ratio of 26.6 is extremely high, reflecting ample liquidity, but the company will need to rely on the AbbVie acquisition for a cash exit rather than organic cash generation. ROE is -28.3%, reflecting the net losses relative to shareholders' equity.
Quarterly Revenue
$0.0B
2025-12
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
$-232597000.0B
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is APGE Overvalued?
Since Apogee has negative net income and negative EBITDA, the most appropriate valuation metric is the price-to-sales (P/S) ratio, but the company has zero revenue, making P/S undefined. Therefore, we must rely on the price-to-book (P/B) ratio and the implied acquisition value. The trailing P/E is -17.9x and forward P/E is -25.8x, both meaningless due to negative earnings. The P/B ratio of 5.07x is the most relevant fundamental multiple, though it is elevated for a biotech with no revenue and significant losses.
Comparing to the biotechnology industry, the average P/B ratio for the sector is approximately 3.5x, so Apogee's 5.07x represents a 45% premium. This premium is justified by the acquisition premium embedded in the stock price, as AbbVie's $10.9 billion offer values the company at a significant multiple of book value. Without the acquisition, the P/B would likely be lower given the lack of revenue and ongoing losses. The premium reflects the strategic value of Apogee's pipeline to AbbVie rather than standalone fundamentals.
Historically, Apogee's P/B ratio has ranged from 2.6x (Q3 2023) to 9.5x (Q2 2023), with the current 5.07x near the middle of that range. The trailing P/E has been consistently negative, ranging from -9.2x to -25.4x over the past two years. The current valuation is not near historical extremes, but the acquisition has reset expectations. The forward P/E of -25.8x implies the market expects continued losses, which is consistent with a pre-revenue biotech. The valuation is now driven by the acquisition price rather than standalone fundamentals.
PE
-17.9x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -148x~-9x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-17.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Apogee's primary financial risk is its pre-revenue status with no product sales and widening net losses of $69.4 million in Q4 2025, up from $67.2 million a year ago. The company burns cash at a significant rate, with TTM free cash flow of -$232.6 million, and has only $131.5 million in cash, which may not sustain operations for more than a few quarters without the acquisition. The negative ROE of -28.3% and ROA of -19.0% reflect deep unprofitability, and the reliance on the AbbVie deal for a cash exit means any delay could force dilutive financing.
Market & Competitive Risks: The stock's elevated P/B ratio of 5.07x versus the biotech industry average of 3.5x implies a 45% premium that is only justified by the acquisition premium. If the deal fails, the stock could revert to a lower multiple, potentially falling to the 52-week low of $34.34. The low beta of 0.325 suggests limited market correlation, but the high short ratio of 9.81 days indicates significant bearish sentiment that could amplify a downside move. Regulatory risks include antitrust review of the acquisition, and competitive risks from other immunology players like Sanofi or Regeneron could reduce the pipeline's perceived value.
Worst-Case Scenario: The most damaging scenario would be the AbbVie acquisition failing due to regulatory opposition or shareholder disapproval. In that case, the stock could fall to the pre-announcement level of ~$90 or even lower to the 52-week low of $34.34, representing a downside of 33% to 74% from the current price of $133.65. Historical max drawdown of -26.99% provides a reference for potential losses, but a deal failure could exceed that given the stock's reliance on the acquisition.
FAQ
The primary risk is acquisition failure, which could cause the stock to drop to pre-announcement levels around $90 or lower, representing a 33% downside. Financial risks include zero revenue and widening net losses of $69.4 million in Q4 2025, with a cash burn rate that requires the acquisition for a cash exit. Valuation risk is elevated, with a P/B ratio of 5.07x versus the industry average of 3.5x, implying a 45% premium that is unsustainable without the deal. Additionally, the high short ratio of 9.81 days indicates significant bearish sentiment that could exacerbate any negative news.
The 12-month forecast is dominated by the AbbVie acquisition, with a 70% probability of the bull case where the stock converges to $133.87. The base case (20% probability) sees the stock trading between $120 and $133 due to minor delays. The bear case (10% probability) involves deal failure, with a target range of $34.34 to $90. The most likely scenario is the bull case, assuming regulatory and shareholder approvals are obtained. The stock's current price of $133.65 already reflects high confidence in the deal, so the upside is limited but the downside is well-defined.
APGE is fairly valued relative to the AbbVie acquisition price of $133.87, but overvalued on a standalone basis. The trailing P/E of -17.9x and forward P/E of -25.8x are meaningless due to negative earnings. The P/B ratio of 5.07x is 45% above the biotech industry average of 3.5x, reflecting the acquisition premium. Without the deal, the stock would likely trade at a lower multiple, potentially around the 52-week low of $34.34. The market is pricing in a high probability of deal completion, which justifies the current valuation, but any risk of failure would make the stock significantly overvalued.
APGE is a good buy for investors seeking a low-risk merger arbitrage opportunity, as the stock trades at $133.65, just 0.2% below the implied acquisition price of $133.87 from AbbVie's $10.9 billion deal. The upside is modest but near-certain, with a 70% probability of the deal closing successfully. However, the stock is not suitable for long-term investors due to zero revenue, widening losses ($69.4 million in Q4 2025), and a P/B ratio of 5.07x that is only justified by the acquisition premium. The biggest downside risk is deal failure, which could cause a 33% drop to $90 or more. For risk-tolerant arbitrageurs, it is a good buy; for fundamental investors, it is not.
APGE is suitable for short-term investment, specifically as a merger arbitrage play with a holding period of 6-12 months until the AbbVie acquisition closes. The stock's beta of 0.325 indicates low market correlation, and the lack of revenue and negative earnings make it unsuitable for long-term holding. The company pays no dividend, and the investment thesis relies entirely on the deal's completion. Long-term investors should avoid APGE due to the pre-revenue status and cash burn, but short-term arbitrageurs can capture the remaining spread to the acquisition price.
